作者
Robert K Hills, Sylvie Castaigne, Frederick R Appelbaum, Jacques Delaunay, Stephen Petersdorf, Megan Othus, Elihu H Estey, Hervé Dombret, Sylvie Chevret, Norbert Ifrah, Jean-Yves Cahn, Christian Récher, Lucy Chilton, Anthony V Moorman, Alan K Burnett
发表日期
2014/8/1
来源
The lancet oncology
卷号
15
期号
9
页码范围
986-996
出版商
Elsevier
简介
Background
Gemtuzumab ozogamicin was the first example of antibody-directed chemotherapy in cancer, and was developed for acute myeloid leukaemia. However, randomised trials in which it was combined with standard induction chemotherapy in adults have produced conflicting results. We did a meta-analysis of individual patient data to assess the efficacy of adding gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia.
Methods
We searched PubMed for reports of randomised controlled trials published in any language up to May 1, 2013, that included an assessment of gemtuzumab ozogamicin given to adults (aged 15 years and older) in conjunction with the first course of intensive induction chemotherapy for acute myeloid leukaemia (excluding acute promyelocytic leukaemia) compared with chemotherapy alone. Published data were supplemented with …
学术搜索中的文章
RK Hills, S Castaigne, FR Appelbaum, J Delaunay… - The lancet oncology, 2014